{"owner": "ArrayExpress Uploader", "ownerprofile_id": "arrayexpress_sid", "id": 2513, "factors": [{"GSM1095886": {"GLEASON SCORE": "GS 8", "PSA LEVEL": "PSA 234ng/ml", "CLINICAL STAGE": "clinical T3aN1M0", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095885": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 80ng/ml", "CLINICAL STAGE": "clinical T3aN0M0", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095884": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 275ng/ml", "CLINICAL STAGE": "clinical T3bN0M0", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095883": {"GLEASON SCORE": "GS 8", "PSA LEVEL": "PSA 1000ng/ml", "CLINICAL STAGE": "clinical T3bN1M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095882": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 311ng/ml", "CLINICAL STAGE": "clinical T4N1M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM109588": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 334ng/ml", "CLINICAL STAGE": "clinical T3bN0M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095880": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 630ng/ml", "CLINICAL STAGE": "clinical T3aN0M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095879": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA1900ng/ml", "CLINICAL STAGE": "clinical T2bN1M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095878": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 4427ng/ml", "CLINICAL STAGE": "clinical T4N1M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095877": {"GLEASON SCORE": "GS 9", "PSA LEVEL": "PSA 5477ng/ml", "CLINICAL STAGE": "clinical T4N0M1", "ORGANISM PART": "prostate cancer cells"}}, {"GSM1095876": {"GLEASON SCORE": "not specified", "PSA LEVEL": "not specified", "CLINICAL STAGE": "not specified", "ORGANISM PART": "normal prostate (NP) epithelial cells"}}], "pop_total": 0, "platform": 4, "summary_wrapped": "To identify molecules to serve as diagnostic markers for high-grade prostate cancer (PC) and targets for novel therapeutic drugs, we...", "pubmed_id": 19956859, "geo_gse_id": "E-GEOD-45016", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 4, "sample_count": 11, "tags": ["androgen", "cancer", "prostate", "prostate cancer"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "expression-data-from-high-grade-prostate-cancer-ce", "geo_id_plat": "E-GEOD-45016_A-AFFY-44", "name": "Expression data from High-grade prostate cancer cells", "created": "Jul.12, 2014", "summary": "To identify molecules to serve as diagnostic markers for high-grade prostate cancer (PC) and targets for novel therapeutic drugs, we investigated the gene expression profiles of high-grade PCs using a cDNA microarray combined with laser microbeam microdissection. For this study, we collected 10 frozen specimens from high-grade PCs with high PSA levels and high Gleason score (GS) in clinically using prostatic needle biopsy. All needle biopsy specimens were at clinical stages T2 to T4 with or without N1 and M1 and their GS were 8-9. Moreover, all 10 patients had not received androgen ablation therapy. Simultaneously, normal prostate (NP) epithelial cells were also microdissected from five non-prostate cancer (BPH) patients. These NP cells from five males were used as a normal mixture control for our cDNA microarray analysis.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-45016", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-45016/samples/"}